Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease

Background Multiple system atrophy (MSA) is a rare neurodegenerative disease characterized by intracellular accumulations of α‐synuclein and nerve cell loss in striatonigral and olivopontocerebellar structures. Epidemiological and clinical studies have reported potential involvement of autoimmune me...

Full description

Saved in:
Bibliographic Details
Published inMovement disorders Vol. 36; no. 2; pp. 449 - 459
Main Authors Shadrin, Alexey A., Mucha, Sören, Ellinghaus, David, Makarious, Mary B., Blauwendraat, Cornelis, Sreelatha, Ashwin A.K., Heras‐Garvin, Antonio, Ding, Jinhui, Hammer, Monia, Foubert‐Samier, Alexandra, Meissner, Wassilios G., Rascol, Olivier, Pavy‐Le Traon, Anne, Frei, Oleksandr, O'Connell, Kevin S., Bahrami, Shahram, Schreiber, Stefan, Lieb, Wolfgang, Müller‐Nurasyid, Martina, Schminke, Ulf, Homuth, Georg, Schmidt, Carsten O., Nöthen, Markus M., Hoffmann, Per, Gieger, Christian, Wenning, Gregor, Gibbs, J. Raphael, Franke, Andre, Hardy, John, Stefanova, Nadia, Gasser, Thomas, Singleton, Andrew, Houlden, Henry, Scholz, Sonja W., Andreassen, Ole A., Sharma, Manu
Format Journal Article
LanguageEnglish
Norwegian
Published Hoboken, USA John Wiley & Sons, Inc 01.02.2021
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Multiple system atrophy (MSA) is a rare neurodegenerative disease characterized by intracellular accumulations of α‐synuclein and nerve cell loss in striatonigral and olivopontocerebellar structures. Epidemiological and clinical studies have reported potential involvement of autoimmune mechanisms in MSA pathogenesis. However, genetic etiology of this interaction remains unknown. We aimed to investigate genetic overlap between MSA and 7 autoimmune diseases and to identify shared genetic loci. Methods Genome‐wide association study summary statistics of MSA and 7 autoimmune diseases were combined in cross‐trait conjunctional false discovery rate analysis to explore overlapping genetic background. Expression of selected candidate genes was compared in transgenic MSA mice and wild‐type mice. Genetic variability of candidate genes was further investigated using independent whole‐exome genotyping data from large cohorts of MSA and autoimmune disease patients and healthy controls. Results We observed substantial polygenic overlap between MSA and inflammatory bowel disease and identified 3 shared genetic loci with leading variants upstream of the DENND1B and RSP04 genes, and in intron of the C7 gene. Further, the C7 gene showed significantly dysregulated expression in the degenerating midbrain of transgenic MSA mice compared with wild‐type mice and had elevated burden of protein‐coding variants in independent MSA and inflammatory bowel disease cohorts. Conclusion Our study provides evidence of shared genetic etiology between MSA and inflammatory bowel disease with an important role of the C7 gene in both phenotypes, with the implication of immune and gut dysfunction in MSA pathophysiology. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Bibliography:Dr. Andreassen is a consultant for HealthLytix.
These authors contributed equally.
Relevant conflicts of interest/financial disclosures
Full list of the European Multiple System Atrophy Study Group members is available in the Supplementary Table.
Funding agencies
This study was funded by the MSA Coalition USA. Dr. Sharma is further supported by Michael J. Fox Foundation, USA Genetic Diversity in PD Program: GAP‐India Grant ID: 17473, and grants from the German Research Council (DFG/SH 599/6–1). This work was supported by the Research Council of Norway (223273, 225989, 248778); South‐East Norway Health Authority (2016–064, 2017–004); KG Jebsen Stiftelsen (SKGJ‐Med‐008); the Austrian Science Fund (F4414); the German Federal Ministry of Education and Research (01ZX1606A, 01ZX1709, 01ZZ9603, 01ZZ0103, 01ZZ0403, 03IS2061A, 03Z1CN22); the EU Joint Program‐Neurodegenerative diseases (COURAGE‐PD, FKZ 01ED1604); and German Research Foundation under Germany's Excellence Strategy – EXC 2167–390884018. This work was also supported in part by the Intramural Research Programs of the National Institute of Neurological Disorders and Stroke (1ZIA NS003154) and the National Institute on Aging (Z01‐AG000949). Dr. Singleton was supported by the Michael J. Fox Foundation for Parkinson's Research. Dr. Hardy received funding support from the Medical Research Council UK (award number MR/N026004/1), and Wellcome Trust (award number 202903/Z/16/Z).
NOTUR/NORSTORE/NS9666S
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.28338